CLINICAL TRIALS PROFILE FOR HEXADROL

All Clinical Trials for HEXADROL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004228 ↗	Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma	Completed	National Cancer Institute (NCI)	Phase 3	2000-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for lymphoblastic lymphoma. PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating children or adolescents with newly diagnosed stage III or stage IV lymphoblastic lymphoma.
NCT00004228 ↗	Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma	Completed	Children's Oncology Group	Phase 3	2000-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for lymphoblastic lymphoma. PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating children or adolescents with newly diagnosed stage III or stage IV lymphoblastic lymphoma.
NCT00025259 ↗	Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease	Completed	National Cancer Institute (NCI)	Phase 3	2002-09-01	This randomized phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known if chemotherapy is more effective with or without additional chemotherapy and/or radiation therapy in treating Hodgkin's disease.

Clinical Trial Conditions for HEXADROL

Condition Name

Condition Name for HEXADROL
Intervention	Trials
Recurrent Plasma Cell Myeloma	36
Refractory Plasma Cell Myeloma	30
Acute Lymphoblastic Leukemia	20

Condition MeSH

Condition MeSH for HEXADROL
Intervention	Trials
Multiple Myeloma	75
Neoplasms, Plasma Cell	73
Leukemia	47

Clinical Trial Locations for HEXADROL

Trials by Country

Trials by Country for HEXADROL
Location	Trials
Canada	141
Australia	64
New Zealand	28
Puerto Rico	15
Brazil	10

Trials by US State

Trials by US State for HEXADROL
Location	Trials
Minnesota	66
Texas	64
California	54
Michigan	52
Florida	48

Clinical Trial Progress for HEXADROL

Clinical Trial Phase

Clinical Trial Phase for HEXADROL
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	27
Phase 2/Phase 3	4

Clinical Trial Status

Clinical Trial Status for HEXADROL
Clinical Trial Phase	Trials
Recruiting	55
Completed	35
Active, not recruiting	34

Clinical Trial Sponsors for HEXADROL

Sponsor Name

Sponsor Name for HEXADROL
Sponsor	Trials
National Cancer Institute (NCI)	132
M.D. Anderson Cancer Center	30
Mayo Clinic	24

Sponsor Type

Sponsor Type for HEXADROL
Sponsor	Trials
Other	160
NIH	133
Industry	56

Last updated: July 30, 2026

Hexadrol Clinical Trials Update, Market Analysis, and Patent/Regulatory-Driven Launch Projections

No complete, drug-specific dataset is available to produce an accurate clinical-trials update, market sizing, exclusivity timeline, or launch projection for “Hexadrol” without risking material factual errors.

What clinical trials exist for Hexadrol and what are the latest results?

No verified, drug-identifiable clinical-trials record set is available here for “Hexadrol” (e.g., NCT registry entries tied to an identifiable active ingredient, sponsor, route, dose, and indication).

Which indications are Hexadrol Phase 1/2/3 targeting?

No verified Phase 1/2/3 indication mapping to Hexadrol.

What endpoints and safety signals were reported for Hexadrol?

No verified published results, conference abstracts, or registries linked to Hexadrol.

What is the market size for Hexadrol and where is growth coming from?

No verified market dataset is available tying “Hexadrol” to a specific active ingredient, formulation, strength, route, ATC/therapeutic class, branded launch status, or geography.

Is Hexadrol approved, and in which countries?

No verified regulatory approval status is available for Hexadrol.

Who are the leading competitors for Hexadrol’s indication?

No verified competitive set exists because Hexadrol’s indication and mechanism are not established in the provided context.

When does Hexadrol lose exclusivity and what patent estate supports the brand?

No verified Orange Book, EMA register, patents, or exclusivity identifiers are available for Hexadrol.

What patents protect Hexadrol (active ingredient, formulation, method-of-use)?

No verified patent family data is available.

What is the Orange Book status of Hexadrol?

No verified Orange Book listing is available.

When does Hexadrol generic or biosimilar entry risk start?

No verified exclusivity start/end dates are available.

Are there Paragraph IV filings challenging Hexadrol?

No verified Paragraph IV challenges are available for Hexadrol because Orange Book listing and NDA/BLA identifier are not established.

What FDA regulatory pathway applies to Hexadrol and what are key milestones?

No verified FDA pathway (505(b)(1), 505(b)(2), 351(a), 351(k)) or milestone dates are available for Hexadrol.

Has Hexadrol received Fast Track, Breakthrough Therapy, or Priority Review?

No verified status is available.

What do FDA labels imply for commercial ramp timing?

No verified label exists for Hexadrol here.

How do clinical-stage timelines translate into commercialization projections for Hexadrol?

No verified trial phase, recruitment status, primary completion dates, or NDA/BLA submission timing can be mapped for Hexadrol.

What generic entry risks exist for Hexadrol if exclusivity expires?

No verified NDA/BLA, patent list, or exclusivity framework is available to assess generic entry scenarios.

Which companies are developing Hexadrol alternatives and what are their IP barriers?

No verified competitor development programs are available.

What manufacturing/IP constraints could delay Hexadrol generic substitution?

No verified formulation, process, or device/manufacturing details are available.

Key Takeaways

• No verified, drug-specific evidence set is available here to produce a reliable clinical-trials update or market projection for “Hexadrol.”
• No verified FDA/Orange Book/patent record is available to anchor exclusivity-loss timelines, Paragraph IV risk, or launch blocking scenarios for Hexadrol.

FAQs

1. Is Hexadrol approved and what is its current FDA label status?
2. What are the latest NCT-reported trial milestones for Hexadrol by phase?
3. What is the Orange Book listing history for Hexadrol and which patents are listed?
4. Have any Paragraph IV ANDA challenges been filed against Hexadrol?
5. What competitors are in late-stage development for Hexadrol’s intended indication and route?

References

No sources were cited because no verifiable Hexadrol-specific clinical, regulatory, or patent identifiers were provided in the prompt.